Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study

被引:9
作者
Gerdes, S. [1 ,11 ]
Hoffmann, M. [2 ]
Asadullah, K. [3 ,4 ]
Korge, B. [5 ]
Mortazawi, D. [6 ]
Kruger, N. [7 ]
Personke, Y. [7 ]
Tabori, S. [7 ]
Gomez, M. [8 ]
Wegner, S. [7 ]
Kreimendahl, F. [7 ]
Taut, F. [9 ]
Sticherling, M. [10 ]
机构
[1] Univ Med Ctr Schleswig Holstein, Psoriasis Ctr Kiel, Dept Dermatol, Campus Kiel, Kiel, Germany
[2] Dermatol Practice Dr Matthias Hoffmann, Witten, Germany
[3] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Berlin, Germany
[4] Prof Dr med Asadullah, Dermatol Practice, Potsdam, Germany
[5] Dermatol Practice Dr Bernhard Korge, Duren, Germany
[6] Dermatol Practice Dr Dariusch Mortazawi, Remscheid, Germany
[7] Janssen Cilag GmbH, MAF, Neuss, Germany
[8] Janssen Global Serv LLC, Raritan, NJ USA
[9] Taut Sci & Serv GmbH, Constance, Germany
[10] Univ Hosp Erlangen, Deutsch Zent Immuntherapie, Dept Dermatol, Erlangen, Germany
[11] Univ Med Ctr Schleswig Holstein, Psoriasis Ctr Kiel, Dept Dermatol, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany
关键词
LONG-TERM EFFICACY; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; MODERATE; TRIAL;
D O I
10.1111/jdv.19296
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundPERSIST was a prospective, non-interventional, real-world study of guselkumab and ustekinumab in adult patients with moderate-to-severe plaque psoriasis in Germany. ObjectivesTo examine effectiveness, safety and quality-of-life (QoL) outcomes to Week (W) 104 of treatment with guselkumab and ustekinumab in patients with moderate-to-severe plaque psoriasis. MethodsPatients (& GE;18 years of age) received guselkumab or ustekinumab as per routine clinical practice. Outcomes to W104 were examined separately in guselkumab and ustekinumab recipients. An ad hoc exploratory analysis of outcomes with guselkumab versus ustekinumab was also performed following propensity score matching. ResultsOverall, 302 and 313 patients received guselkumab and ustekinumab, respectively. Patients in both cohorts experienced improvements in disease activity and QoL that were maintained to W104, with 64.7% and 63.6% of guselkumab- and 54.6% and 64.4% of ustekinumab-treated patients achieving a Psoriasis Area and Severity Index (PASI) 90 response and a Dermatology Life Quality Index (DLQI) 0/1 score, respectively. Propensity score matching yielded well-balanced baseline characteristics except for prior biologic use, which was higher in guselkumab versus ustekinumab recipients (51.7% vs. 32.0%). Achievement of PASI & LE;1 at W104 was more common in guselkumab versus ustekinumab recipients (58.7% vs. 49.7%). The W104 PASI90 response rate was 65.6% with guselkumab and 56.0% with ustekinumab; corresponding rates for PASI100 were 44.3% and 28.5%. In guselkumab recipients, response rates were higher in biologic-naive versus biologic-experienced patients (PASI90, 77.1% vs. 53.4%; PASI100, 55.0% vs. 33.0%). A high level of response for QoL outcomes was observed for both treatments. ConclusionsUstekinumab and guselkumab led to improvements in physician-assessed and patient-reported outcomes that were sustained for up to 2 years, with no new safety signals identified. Following propensity score matching, greater improvements in PASI outcomes were observed with guselkumab versus ustekinumab. Improvements with guselkumab were highest in biologic-naive patients, highlighting the value of early treatment.
引用
收藏
页码:38 / 49
页数:12
相关论文
共 42 条
[1]   Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients [J].
Augustin, M. ;
Sommer, R. ;
Kirsten, N. ;
Danckworth, A. ;
Radtke, M. A. ;
Reich, K. ;
Thaci, D. ;
Boehncke, W. H. ;
Langenbruch, A. ;
Mrowietz, U. .
BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (02) :358-365
[2]   Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience [J].
Bardazzi, Federico ;
Viviani, Filippo ;
Merli, Yuri ;
Di Lernia, Vito ;
Peccerillo, Francesca ;
Conti, Andrea ;
Lasagni, Claudia ;
Tabanelli, Michela ;
D'Adamio, Simone ;
Di Nuzzo, Sergio ;
Cortellazzi, Chiara ;
Filippi, Federica .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) :1561-1566
[3]   Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].
Blauvelt, Andrew ;
Papp, Kim A. ;
Griffiths, Christopher E. M. ;
Randazzo, Bruce ;
Wasfi, Yasmine ;
Shen, Yaung-Kaung ;
Li, Shu ;
Kimball, Alexa B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417
[4]   Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group [J].
del Alcazar, Elena ;
Lopez-Ferrer, Anna ;
Martinez-Domenech, Alvaro ;
Julia, Marc ;
Ruiz-Villaverde, Ricardo ;
Rodriguez Fernandez-Freire, Lourdes ;
Notario, Jaime ;
Llamas-Velasco, Mar ;
Ferran, Marta ;
Carrascosa, Jose Manuel .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (06) :2878-2880
[5]   Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group [J].
del Alcazar, Elena ;
Lopez-Ferrer, Anna ;
Martinez-Domenech, Alvaro ;
Ruiz-Villaverde, Ricardo ;
Llamas-Velasco, Ma. del Mar ;
Rocamora, Vicenc ;
Julia, Marc ;
Notario, Jaime ;
Fernandez-Freire, Lourdes Rodriguez ;
Sahuquillo-Torralba, Antonio ;
Vidal, David ;
Rivera, Raquel ;
Carretero, Gregorio ;
Mateu, Almudena ;
de la Cueva, Pablo ;
Carrascosa, Jose Manuel .
DERMATOLOGIC THERAPY, 2022, 35 (02)
[6]   Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis [J].
Diels, J. ;
Thilakarathne, P. ;
Cameron, C. ;
McElligott, S. ;
Schubert, A. ;
Puig, L. .
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) :276-284
[7]   Guselkumab: Short-term effectiveness and safety in real clinical practice [J].
Fernandez-Freire, Lourdes ;
Galan-Gutierrez, Manuel ;
Armario-Hita, Jose Carlos ;
Perez-Gil, Amalia ;
Ruiz-Villaverde, Ricardo .
DERMATOLOGIC THERAPY, 2020, 33 (03)
[8]   Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study [J].
Fougerousse, A. -C. ;
Ghislain, P. -D. ;
Reguiai, Z. ;
Maccari, F. ;
Parier, J. ;
Auvray, D. Bouilly ;
Chaby, G. ;
Pallure, V. ;
Schmutz, J. -L. ;
Clement, C. ;
Jacobzone, C. ;
Begon, E. ;
Esteve, E. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (10) :E644-E646
[9]   A safety evaluation of guselkumab for the treatment of psoriasis [J].
Galluzzo, M. ;
D'Adamio, S. ;
Campione, E. ;
Bianchi, L. ;
Talamonti, M. .
EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) :741-751
[10]   Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks [J].
Galluzzo, Marco ;
Marcelli, Lorenzo ;
Vellucci, Laura ;
Paganini, Claudia ;
Maffei, Virginia ;
Tofani, Lorenzo ;
Belcastro, Alfredo ;
Bianchi, Luca ;
Talamonti, Marina .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (04) :371-381